SyntekaBio

SyntekaBio Interest Coverage

The Interest Coverage Ratio of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -0.75. In the previous year, Interest Coverage Ratio was -8.43 — a change of -91.15% (higher).

Interest Coverage

-0.75

YoY

-91.15%

Last updated:

Interest Coverage Ratio of SyntekaBio is 2024 -0.75 . Interest Coverage Ratio of SyntekaBio was 2023 -8.43 . It decreases by -91.15% higher compared to the previous year.

The SyntekaBio Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-3.02 KRW
Jan 1, 2018
0.54 KRW
Jan 1, 2019
-0.29 KRW
Jan 1, 2020
-11.70 KRW
Jan 1, 2021
-1.47 KRW
Jan 1, 2022
-1.66 KRW
Jan 1, 2023
-8.43 KRW
Jan 1, 2024
-0.75 KRW
The SyntekaBio Interest Coverage history
YEARInterest CoverageYoY
-0.75-91.15%
-8.43+406.86%
-1.66+13.07%
-1.47-87.43%
-11.70+3,904.59%
-0.29-154.33%
0.54-117.82%
-3.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Interest Coverage Ratio of SyntekaBio is -0.75 in 2024.

Interest Coverage Ratio of SyntekaBio changed from -8.43 to -0.75, representing a -91.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SyntekaBio

All Key Metrics — SyntekaBio